BACKGROUND: Bicuspid aortic valve (BAV) is a heritable condition that has been linked by an unknown mechanism to a predisposition for ascending aortic aneurysm. Matrix metalloproteinases have been implicated in this predisposition. Metallothionein is a poorly characterized, metal-binding protein that regulates matrix metalloproteinases and is an antioxidant known to be upregulated under oxidative stress. METHODS AND RESULTS: To determine putative factors involved in the pathogenesis of aortic aneurysm in BAV patients, our first goal was to identify genes that are dysregulated in ascending aortic aneurysms of BAV patients compared with tricuspid aortic valve patients and nondiseased (control) donors. By microarray analysis (22,000 probe sets), 110 dysregulated genes were identified in BAV compared with tricuspid aortic valve patients and control donors; 8 were genes of the metallothionein family. Metallothionein gene expression and protein expression were significantly lower in aortic tissue and cultured aortic smooth muscle cells from BAV patients compared with control subjects. Matrix metalloproteinase-9 expression was increased in BAV aortic samples relative to controls. BAV aorta was more susceptible to oxidative stress, and induction of metallothionein under oxidative stress was reduced in BAV patients compared with control subjects. CONCLUSIONS: These results demonstrate dysregulated metallothionein expression in ascending aortic smooth muscle cells of BAV patients that may contribute to an inadequate response to oxidative stress and provoke aneurysm formation. We hypothesize that metallothionein plays a pivotal role in the response of ascending aortic smooth muscle cells to oxidative stress cues normally involved in the maintenance of the extracellular matrix, including the regulation of matrix metalloproteinase expression.
BACKGROUND:Bicuspid aortic valve (BAV) is a heritable condition that has been linked by an unknown mechanism to a predisposition for ascending aortic aneurysm. Matrix metalloproteinases have been implicated in this predisposition. Metallothionein is a poorly characterized, metal-binding protein that regulates matrix metalloproteinases and is an antioxidant known to be upregulated under oxidative stress. METHODS AND RESULTS: To determine putative factors involved in the pathogenesis of aortic aneurysm in BAV patients, our first goal was to identify genes that are dysregulated in ascending aortic aneurysms of BAV patients compared with tricuspid aortic valvepatients and nondiseased (control) donors. By microarray analysis (22,000 probe sets), 110 dysregulated genes were identified in BAV compared with tricuspid aortic valvepatients and control donors; 8 were genes of the metallothionein family. Metallothionein gene expression and protein expression were significantly lower in aortic tissue and cultured aortic smooth muscle cells from BAV patients compared with control subjects. Matrix metalloproteinase-9 expression was increased in BAV aortic samples relative to controls. BAV aorta was more susceptible to oxidative stress, and induction of metallothionein under oxidative stress was reduced in BAV patients compared with control subjects. CONCLUSIONS: These results demonstrate dysregulated metallothionein expression in ascending aortic smooth muscle cells of BAV patients that may contribute to an inadequate response to oxidative stress and provoke aneurysm formation. We hypothesize that metallothionein plays a pivotal role in the response of ascending aortic smooth muscle cells to oxidative stress cues normally involved in the maintenance of the extracellular matrix, including the regulation of matrix metalloproteinase expression.
Authors: Lisa J Martin; Vijaya Ramachandran; Linda H Cripe; Robert B Hinton; Gregor Andelfinger; Meredith Tabangin; Kerry Shooner; Mehdi Keddache; D Woodrow Benson Journal: Hum Genet Date: 2007-01-04 Impact factor: 4.132
Authors: H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin Journal: Nature Date: 1991-07-25 Impact factor: 49.962
Authors: A M Segura; R E Luna; K Horiba; W G Stetler-Stevenson; H A McAllister; J T Willerson; V J Ferrans Journal: Circulation Date: 1998-11-10 Impact factor: 29.690
Authors: Scott A LeMaire; Xinwen Wang; Jonathan A Wilks; Stacey A Carter; Shixiang Wen; Taehee Won; Dominic Leonardelli; Gobind Anand; Lori D Conklin; Xing Li Wang; Robert W Thompson; Joseph S Coselli Journal: J Surg Res Date: 2005-01 Impact factor: 2.192
Authors: Jon Boyum; Erika K Fellinger; Joseph D Schmoker; Lucy Trombley; Kenneth McPartland; Frank P Ittleman; Alan B Howard Journal: J Thorac Cardiovasc Surg Date: 2004-03 Impact factor: 5.209
Authors: Lasse Folkersen; Dick Wågsäter; Valentina Paloschi; Veronica Jackson; Johan Petrini; Sanela Kurtovic; Shohreh Maleki; Maria J Eriksson; Kenneth Caidahl; Anders Hamsten; Jean-Baptiste Michel; Jan Liska; Anders Gabrielsen; Anders Franco-Cereceda; Per Eriksson Journal: Mol Med Date: 2011-09-27 Impact factor: 6.354
Authors: Julie A Phillippi; Jennifer C Hill; Marie Billaud; Benjamin R Green; Mary P Kotlarczyk; Thomas G Gleason Journal: Ann Thorac Surg Date: 2017-02-06 Impact factor: 4.330
Authors: Marie Billaud; Julie A Phillippi; Mary P Kotlarczyk; Jennifer C Hill; Bradley W Ellis; Claudette M St Croix; Nadiezhda Cantu-Medéllin; Eric E Kelley; Thomas G Gleason Journal: J Thorac Cardiovasc Surg Date: 2017-05-25 Impact factor: 5.209
Authors: Emanuela Branchetti; Paolo Poggio; Rachana Sainger; Eric Shang; Juan B Grau; Benjamin M Jackson; Eric K Lai; Michael S Parmacek; Robert C Gorman; Joseph H Gorman; Joseph E Bavaria; Giovanni Ferrari Journal: Cardiovasc Res Date: 2013-08-28 Impact factor: 10.787
Authors: Julie A Phillippi; Benjamin R Green; Michael A Eskay; Mary P Kotlarczyk; Michael R Hill; Anne M Robertson; Simon C Watkins; David A Vorp; Thomas G Gleason Journal: J Thorac Cardiovasc Surg Date: 2013-06-12 Impact factor: 5.209